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Abstract
Background: Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients on opioid agonist
therapy (OAT) are common and have pros and cons. The objectives of the current study are to define the
dispensation rates of these potentially addictive drugs, and whether the number and the mean daily doses of
dispensed OAT opioids and discontinuing OAT, are associated with being dispensed benzodiazepines, z-hypnotics
and gabapentinoids among patients on OAT in Norway in the period 2013 to 2017.
Methods: Information about all dispensed opioids, benzodiazepines, z-hypnotics and gabapentinoids were
recorded from the Norwegian Prescription Database (NorPD). A total of 10,371 OAT patients were included in the
study period. The dispensation rates were defined as the number of patients who were dispensed at least one of
the potentially addictive drugs divided among the number of patients who have dispensed an OAT opioid per
calendar year. Mean daily doses were calculated, and for benzodiazepines and z-hypnotics, stated in diazepam
equivalents. The association between dispensed potentially addictive drugs, and the number and the type of
dispensed OAT opioids were calculated by using logistic regression models.
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Results: Half of the OAT patients received at least one dispensation of a benzodiazepine or z-hypnotic, and 11%
were dispensed at least a gabapentinoid in 2017. For dispensed benzodiazepines or z-hypnotics, the mean daily
dose was reduced from 21mg (95% confidence interval (CI): 20–23) diazepam equivalents in 2013 to 17 mg (95%
CI: 16–17) in 2017. The mean daily dose of pregabalin increased from 365 mg (95% CI: 309–421) in 2013 to 386 mg
(95% CI: 349–423) in 2017. Being dispensed a gabapentinoid (adjusted odds ratio (aOR) = 2.5, 95% CI: 2.1–3.0) or a
non-OAT opioid (aOR = 3.0, 95% CI: 2.6–3.5) was associated with being dispensed a benzodiazepine or z-hypnotic.
Discontinuing OAT did not affect the number of dispensations and the doses of potentially addictive drugs.
Conclusion: The dispensation rates of potentially addictive drugs are high in the OAT population. Treatment
indications, as well as requirements for prescription authority, need to be debated and made explicit. Randomized
controlled trials evaluating the benefits and risks of such co-prescription are required.
Keywords: Opioid substitution treatment, Benzodiazepines, Zopiclone, Zolpidem, Pregabalin, Gabapentin, Opioids,
Drug prescriptions
Background
Dispensations of benzodiazepines, z-hypnotics, and
gabapentinoids to patients on opioid agonist therapy
(OAT) have pros and cons. These drugs may increase
the mortality among patients on OAT and are associated
with criminality, psychosocial problems, and injecting
drug use [1, 2]. The use of several potentially addictive
drugs is particularly challenging in an OAT program
aimed at reducing mortality and injecting drug use and
achieve rehabilitation among marginalized and comorbid
patients with opioid addiction [3–8]. However, dispensa-
tions of benzodiazepines among highly comorbid patients
with polydrug use may decrease the mortality if such dis-
pensations make patients abstinent of illegal drugs, and
they are followed up strictly by health professionals [2].
The proportion of OAT patients who were dispensed
benzodiazepines or z-hypnotics varies across countries.
In the United Kingdom, the proportion of OAT patients
who were dispensed benzodiazepines and z-hypnotics
was 42 and 20%, respectively, between 1998 and 2014
[9]. In Sweden, 32% of OAT patients were dispensed a
benzodiazepine, and 41% received a z-hypnotic in the
period from 2005 to 2012 [1]. Further, the proportion of
Norwegian OAT patients who were dispensed benzodi-
azepine was 40% in 2005. Regulations of OAT are a typ-
ical reason for differences in the proportion of patients
who are dispensed, potentially addictive drugs between
countries [10]. In some countries, OAT has been a subject
for strict regulation, implying that OAT is stopped if used
potentially addictive drugs concomitantly [11–13]. Others,
e.g., Norway, such discontinuation of OAT in case of
benzodiazepine, and z-hypnotic use has become less com-
mon compared to during the early 2000s [14, 15].
The knowledge of gabapentinoid use among patients
on OAT is lacking. However, for the last couple of years,
gabapentinoids, particularly pregabalin, are consumed
significantly more often among patients with opioid ad-
diction compared to patients with other drug addictions
[16]. Withdrawal symptoms are described if dose reduc-
tion or discontinuation [17–20], while using high-dosed
gabapentinoids may cause euphoric effects, sedation, hal-
lucinations, dissociation, conspicuous behavior, and the
reinforced effect of OAT opioids [8, 16]. Dispensing
gabapentinoids among patients with opioid addiction
not necessarily indicated misuse or addiction. However,
it is worrying if adverse side effects occur when combin-
ing with highly potent opioids with OAT opioids [16].
In Norway, opioid agonist therapy has been applied in-
creasingly as an available treatment approach for opioid
addiction [15]. In 2017, about 7500 patients received
OAT opioids, and the majority received their OAT opi-
oids at least once per week from pharmacies. A decreas-
ing proportion of patients discontinued OAT during the
past few years, and in 2017, 681 patients, including those
who died, left the treatment [15]. Although, little is
known about dispensations of benzodiazepines and z-
hypnotics and gabapentinoids among patients on OAT.
Thus, this observational study aims to investigate the
dispensation rates and doses of these potentially addict-
ive drugs among patients who were dispensed at least
one OAT opioids in Norway in the period 2013 to 2017
and those who discontinued OAT. This study has three
objectives:
(1) To define dispensation rates and mean daily dose of
benzodiazepines, z-hypnotics, and gabapentinoids
per calendar year.
(2) To assess the association between OAT opioids in
terms of the number of dispensations and mean
daily dose of OAT opioids, and whether patients
are dispensed a benzodiazepine, z- hypnotic, or
gabapentinoid, or not per calendar year.
(3) To evaluate whether discontinuations of OAT affect
the number of dispensations and the mean daily
dose of dispensed benzodiazepines and z-hypnotics,
or gabapentinoids.
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Methods
Data source
All data were register data and were drawn from the
Norwegian Prescription Database (NorPD) (www.norpd.
no). From January 1, 2004, all pharmacies in Norway are
obliged by law to submit all the dispensed drugs data
electronically to the Norwegian Institute of Public
Health. NorPD contains information of all dispensed
drugs, including reimbursements, dispensed from phar-
macies in Norway, except for dispensations dispensed
during hospitalizations or at outpatient clinics. Anatom-
ical Therapeutic Chemical (ATC) classification system
was employed according to the determination by the
World Health Organization (WHO) collaborating centre
for drug statistics per October 2018 [21]. NorPD data
were collected from January 1, 2013, to March 31, 2018,
in this study. The STROBE checklist was applied in the
preparation of the study (Additional file 1).
Study population
All patients above 18 years of age who received at least
one dispensation of an OAT opioid, including methadone,
levomethadone, buprenorphine, and buprenorphine-
naloxone, from January 1, 2013, to December 31, 2017,
were included. The patients using methadone tablets to
achieve pain relief in palliative care were excluded by iden-
tifying those who only were dispensed methadone tablets
without any dispensations of other OAT opioids or
methadone mixture in the period from January 1, 2004, to
December 31, 2017. Discontinuing OAT was defined as
all patients who had the last dispensation of an OAT opi-
oid in the inclusion period from January 1, 2017, to Sep-
tember 30, 2017, and then, no dispensations until the end
of the collected NorPD data on March 31, 2018.
Analysis strategy and statistical analyses
Definitions of opioids, benzodiazepines, z-hypnotics,
gabapentinoids, age, the number of dispensations, mean
daily doses, and the type of dispensed OAT opioid
Opioid agonist therapy opioids, non-OAT opioids, and
gabapentinoids, including gabapentin and pregabalin, were
defined according to their ATC codes (Additional file 2).
Benzodiazepines and z-hypnotics were defined as all benzo-
diazepines and z-hypnotics that have or have had marketing
authorizations in Norway during the study period, including
alprazolam, clonazepam, diazepam, flunitrazepam, nitraze-
pam, oxazepam, zolpidem, and zopiclone. Dispensations of
benzodiazepines and z-hypnotics were pooled.
All included OAT patients were categorized into age
groups per calendar year. The age groups were ≤ 25, 26–
35, 36–45, 46–55, and ≥ 56. The number of dispensa-
tions was defined as all dispensations of a drug per cal-
endar year. Further, the type of OAT opioid was defined
as the last type of opioid that was dispensed per year.
The mean daily doses of benzodiazepines, z-hypnotics,
and gabapentinoids per year were calculated by using
daily defined doses (DDD) stated in NorPD defined by
the WHOs standards [21]. For benzodiazepines and z-
hypnotics, dispensed DDDs of each benzodiazepine or z-
hypnotic were summarized per year and converted to
milligrams. For each benzodiazepine or z-hypnotic, the
doses per year (in milligrams) were converted to diazepam
equivalents, according to a benzodiazepine and z-hypnotic
equipotency table stated in the Norwegian national guide-
lines for addictive drugs (Additional file 3) and WHOs
standards [21, 22]. The total doses of each benzodiazepine
or z-hypnotic were summarized (in diazepam equivalents)
and divided on 365.25 days to calculate the mean daily
doses per year. For gabapentinoids, the number of DDDs
of gabapentin and pregabalin, respectively, were summa-
rized per calendar year, and further, converted to milli-
grams by using WHOs standards [21]. The total
dispensed doses of pregabalin and gabapentin were di-
vided similarly on 365.25 days to calculate the mean daily
dose per year. For OAT opioids, the number of DDDs of
any defined OAT opioid were summarized and divided
this by the number of days between the date of the first
and the last dispensation per year. Due to this estimation,
all patients that only were dispensed one dispensation of
an OAT opioid per year were censored.
Moreover, patients were stratified into different cat-
egories according to the number of dispensations and
the mean daily doses of dispensed benzodiazepines and
z-hypnotics, gabapentinoids, and OAT opioids, respect-
ively. Benzodiazepines and z-hypnotics, and gabapenti-
noids had three dispensation groups: 0, 1–2, and ≥ 3
dispensations per calendar year, and the OAT opioids
were categorized into four groups: 1–6, 7–12, 13–51,
and ≥ 52 dispensations per calendar year. Benzodiaze-
pines and z-hypnotics were divided into three groups ac-
cording to the mean daily doses (in milligrams) were
dispensed: 0, ≤20, > 20 - ≤40, and > 40 diazepam equiva-
lents. The mean daily doses of pregabalin and gabapen-
tin were categorized into three groups. For pregabalin
(mg per day): > 0 - ≤300, > 300 - ≤600, and > 600, and
for gabapentin (mg per day): > 0 - ≤900, > 900 - ≤3600,
> 3600. OAT opioids were defined as the mean daily
DDDs, and the following three groups were used: 0- < 1,
1- < 2, and ≥ 2 mean DDDs per day. The ratio between
DDD and milligrams are presented in Additional file 3.
Analysis strategy according to the aims
Dispensation rates were defined as all OAT patients who
were dispensed one or more of the defined benzodiazepines
or z-hypnotics, or gabapentinoids, respectively, per calendar
year divided on all included OAT patients the same year.
Diazepam equivalents were used to adjust for equipo-
tency of benzodiazepines and z-hypnotics. Due to the
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absence of consistent international guidelines of equipo-
tency for these drugs, a sensitivity analysis was conducted
[22]. The lowest and highest stated equipotency for each
benzodiazepine and z-hypnotic, as well as a mean of them,
respectively, were used to create three equipotency equa-
tions to convert all dispensed doses per year of each benzo-
diazepine or z-hypnotic into diazepam equivalents. The
mean equivalent equation was as follow (in milligrams
(mg)):














The lowest and the highest equivalent equations are
presented in Additional file 4.
The number of dispensations of benzodiazepines and
z-hypnotics, gabapentinoids, and OAT opioids, respect-
ively, was plotted against the number of dispensations of
an OAT opioid per year. Furthermore, the mean daily
doses of dispensed benzodiazepines and z-hypnotics,
and gabapentinoids, respectively, were plotted against
mean daily DDD of OAT opioids per year.
The associations between being dispensed a benzodiazep-
ine or z-hypnotic, or a gabapentinoid, and age, gender, type
of OAT opioid, the number of dispensed OAT opioids, and
being dispensed a non-OAT opioid were assessed per cal-
endar year by using logistic regression models.
Dispensation rates and the mean daily doses of ben-
zodiazepines and z-hypnotics, and gabapentinoids were
evaluated for patients who discontinued OAT. For the
baseline, the dispensation rates and the mean daily
doses of dispensed benzodiazepines or z-hypnotics
(stated in diazepam equivalents), and gabapentinoids,
respectively, were calculated for the period 180 to 90
days before discontinuation date. Furthermore, the
dispensation rates and the mean daily doses of benzodi-
azepines or z-hypnotics, and gabapentinoids, during the
last 90 days before and the 90 days after discontinuation
date, respectively, were summarized separately and
Table 1 Baseline characteristics of patients on opioid agonist therapy in Norway
Baseline characteristics 2013 2014 2015 2016 2017
No. % No. % No. % No. % No. %
Patients 7709 7914 7958 7804 7709
Deaths 165 151 138 114 124
Patients, excl. deaths 7544 7763 7820 7690 7585
Age
- ≤ 25 211 3 185 2 171 2 135 2 120 2
- 26-35 1590 21 1570 20 1551 20 1403 18 1333 18
- 36-45 2724 36 2730 35 2605 33 2508 33 3292 32
- 46-55 2283 30 2449 32 2544 33 2540 33 2548 34
- ≥ 56 736 10 829 11 949 12 1104 14 1192 16
Mean (SD) 43 (10) 44 (10) 44 (10) 44 (10) 45 (10)
Gender
Men 5221 69 5390 69 5430 69 5354 70 5245 69
Women 2323 31 2373 31 2390 31 2336 30 2340 31
OAT opioidsa
Methadone, included levomethadone 3406 45 3264 42 3216 41 3066 40 2981 39
Buprenorphineb 4138 55 4499 58 4604 59 4624 60 4604 61
Potentially addictive drugs
Dispensed a benzodiazepine and z-hypnoticc 3747 50 3809 49 3714 47 3758 49 3762 50
Dispensed a gabapentinoid 708 9 662 9 717 9 762 10 845 11
NorPD Norwegian Prescription Database, OAT Opioid agonist therapy, SD Standard deviation
aThe last type of dispensed OAT opioid per year
bInclude buprenorphine-naloxone
cZ-hypnotic includes zolpiclone and zolpidem
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compared to dispensation rates and mean daily doses at
baseline.
Statistical analyses
Means, median, percentiles, percentage, 95% confidence
interval (CI), odds ratio (OR), and p-value are presented
when appropriate. The one-sample t-test was used to
calculate mean daily doses of dispensed benzodiazepines
or z-hypnotics, or gabapentinoids with 95% CI. The
paired sample t-test was used to compare the differences
in the mean daily dose of benzodiazepines or z-
hypnotics and gabapentinoids, respectively, per year
among OAT patients who discontinued OAT. Multivari-
able analyses for categorical variables were performed
per year by creating logistic regression models. For these
models, being dispensed a gabapentinoid, or a benzodi-
azepine or z-hypnotic were dependent variables, respect-
ively, per year. Age groups, gender, type of OAT opioid,
the number of dispensed OAT opioids, and being dis-
pensed a non-OAT opioid were independent variables
and defined categorically. In addition, being dispensed a
gabapentinoid was used as an independent and categor-
ical variable when being dispensed a benzodiazepine, or
a z-hypnotic was defined as a dependent variable, and
vice versa. The level of statistical significance was p <
0.05. All patients were excluded from the calendar year
they died. SPSS version 24 was used for all analyses.
Ethical considerations
The Regional Committee for Medical and Health Re-
search Ethics, REC vest, Norway, has approved the use
of registry data for the study (approval number 2018/
939/REK Vest, June 19, 2018). No informed consent
from included patients was necessary.
Results
Basic characteristics
A total of 10,371 patients were dispensed at least one
OAT opioid from pharmacies in Norway in the period
2013 to 2017 (Table 1). In 2017, 69% were men. The
mean age increased from 43 (standard deviation (SD):
10) years in 2013 to 45 (SD: 10) years in 2017. A total of
690 participants died during the study period.
Dispensation rates and mean daily doses of dispensed
benzodiazepines, z-hypnotics, and gabapentinoids
The proportion of patients who received at least one
dispensation of benzodiazepines or z-hypnotics was 50%
in 2017, and 42% received three or more such dispensa-
tions (Fig. 1). Similar findings were found yearly from
2013 to 2016. The dispensation rates of benzodiazepines
Fig. 1 The proportion of patients on OAT were dispensed a benzodiazepine or z-hypnotic, and a gabapentinoid. Legend: OAT = opioid agonist
therapy. The figures display the proportion of patients who were dispensed 1–2 or 3 or more dispensations of benzodiazepines or z-hypnotics
and gabapentinoids, respectively, of those who dispensed an OAT opioid per calendar year in the study period. Each figure a) to d) displays
patients on OAT categorized on the number of dispensations of OAT opioids per year: a) 1–6 dispensations, b) 7–12 dispensations, c) 13–51
dispensations, and d) 52 or more dispensations
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and z-hypnotics declined from 21mg (95% CI: 20–23
mg) diazepam equivalents per day in 2013 to 17 mg
(95% CI: 16–17mg) diazepam equivalents per day in
2017 (Table 2a and Table 2b). A quarter of patients was
dispensed oxazepam, which was the most frequently dis-
pensed benzodiazepine per year throughout the study
period (Table 3). Zopiclone was the most frequently dis-
pensed z-hypnotic per patient per year.
Gabapentinoids were dispensed to 9 % of the patients
in 2013 and 11% of the patients in 2017. Pregabalin was
almost twice as frequently dispensed per patient as gaba-
pentin per year throughout the study period. The mean
daily doses of dispensed pregabalin increased with 1%
per year from 365mg (95% CI: 309–421 mg) in 2013 to
386 mg (95% CI: 349–423 mg) in 2017, and gabapentin
increased with 4% per year from 911mg (95% CI: 753–
1068 mg) to 1047mg (95% CI: 885–1209 mg) in the
same period.
The dispensation rates of benzodiazepines and z-
hypnotics, and gabapentinoids related to the number of
dispensations and mean daily DDD of dispensed OAT
opioids
The number of dispensations and the mean daily DDD
of OAT opioids was not associated with changes in dis-
pensation rates or the number of dispensations of ben-
zodiazepines and z-hypnotics or gabapentinoids per year
in the study period (Additional files 5, 6 and 7). However,
Table 2 The daily doses of dispensed potentially addictive drugs
a)
All indications 2013 2014 2015 2016 2017
Benzodiazepine and z-hypnotic dose per
patient (in diazepam equivalents)
mean (lowest-highest)
Mean (mg/day) 21 (17–29) 20 (16–27) 19 (15–25) 17 (14–23) 17 (14–22)
Median (mg/day) 10 (9–12) 10 (9–12) 10 (8–12) 10 (8–12) 10 (8–11)
25 percentile (mg/day) 3 (2–3) 2 (2–3) 3 (2–3) 3 (2–3) 3 (2–3)
75 percentile (mg/day) 23 (20–29) 22 (19–27) 21 (18–26) 21 (18–26) 20 (18–25)
All indications 2013 2014 2015 2016 2017
Pregabalin dose per patient Mean (mg/day) 365 365 371 381 386
Median (mg/day) 205 230 249 285 255
25 percentile (mg/day) 46 74 62 84 69
75 percentile (mg/day) 506 552 552 561 552
All indications 2013 2014 2015 2016 2017
Gabapentin dose per patient Mean (mg/day) 911 970 997 960 1047
Median (mg/day) 411 488 493 493 513
25 percentile (mg/day) 82 124 82 82 164
75 percentile (mg/day) 1228 1314 1383 1286 1430
b)
All indications 2013 2017
Mean dose (95 % CI) Mean dose (95% CI)
Diazepam equivalents per patient
Benzodiazepine and z-hypnotic dose per
patient (in diazepam equivalents)
Mean (mg/day) 21 (20–23)a 17 (16–17)b
Pregabalin dose per patient Mean (mg/day) 365 (309–421)c 386 (349–423)d
Gabapentin dose per patient Mean (mg/day) 911 (753–1068)e 1047 (885–1209)f
Df Degrees of freedom, Lowest Lowest equipotency dose, Highest Highest equipotency dose, and Mean =Min +Max divided by 2
aOne sample t-test, df = 3746, bone sample t-test, df = 3761, cone sample t-test, df = 486, done sample t-test, df = 590, eone sample t-test, df = 260, and fone sample
t-test, df = 309
The table a) displays the daily doses (mean, median, 25 percentile, and 75 percentile) of dispensed benzodiazepines or z-hypnotics (calculated in diazepam
equivalents), pregabalin and gabapentin per year among patients on OAT in Norway in period 2013 to 2017
The table b) displays the mean daily doses of dispensed benzodiazepines or z-hypnotics (calculated in diazepam equivalents), pregabalin and gabapentin in 2013
and 2017. The 95% confidence intervals were calculated by one-sample t-test analyses
For table a) and b), an equipotency table for benzodiazepines and z-hypnotics were used to make sensitivity analyses displaying the lowest equipotency dose and
the highest equipotency dose of the included benzodiazepines and z-hypnotics. The results were presented in parentheses. All dispensed benzodiazepines and z-
hypnotics were summarized per year
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being dispensed a benzodiazepine or z-hypnotic was asso-
ciated with aging 46–55 years or being above 56 years of
age rather than aging below 25 years, gender women,
using methadone rather than buprenorphine as OAT opi-
oid, or being dispensed at least one dispensation of non-
OAT opioids, or gabapentinoids in 2017 (Table 4, Add-
itional file 8). Further, being dispensed a gabapentinoid
was associated with being dispensed a benzodiazepine or
z-hypnotic or a non-OAT opioid. Similar results were
substantially found per year in the period 2013 to 2016.
Dispensation rates and mean daily doses of dispensed
benzodiazepines and z-hypnotics, and gabapentinoids
related to discontinuation of OAT
We identified 693 patients who discontinued OAT during
the inclusion period. Of those, 156 patients were dispensed
at least one dispensation of a benzodiazepine or z-hypnotic
in the period from 180 days before to 90 days after discon-
tinuation. The mean daily dose of dispensed benzodiazep-
ine and z-hypnotic was not changed compared to the mean
daily dose at baseline when patients discontinued OAT (Δ
mean daily dose (in mg): 0, 95% CI: − 3 – 3) (Fig. 2).
Furthermore, 42 patients were dispensed a benzodiazepine
or z-hypnotic only during the 90 days after discontinuation.
Of these patients, the mean daily dose of benzodiazepines or
z-hypnotics during the 90 days after discontinuation was
about half of the mean daily dose of these patients who were
dispensed benzodiazepines or z-hypnotics at baseline and
until 90 days after the discontinuation. Pregabalin and gaba-
pentin were prescribed to 50 and 23 patients, respectively,
during the 180 days before to 90 days after discontinuation
of OAT (Additional file 9). No changes in mean daily doses
of these drugs were found when comparing the mean daily
doses at baseline with the mean daily doses the first 90 days
after the discontinuation (pregabalin: Δ mean daily dose (in
mg): 50, 95% CI: − 47 – 149, gabapentin: Δ mean daily dose
(in mg): 190 mg, 95% CI: − 789 – 1168).
Discussion
In the period 2013 to 2017, a steady proportion of the
Norwegian OAT population received at least one pre-
scription of a benzodiazepine or z-hypnotic. Further-
more, the number of patients who were dispensed at
least one dispensation of a gabapentinoid increased
slightly in the study period. The mean daily dose of ben-
zodiazepines and z-hypnotics was declining, while the
mean daily dose of pregabalin and gabapentin were in-
creasing. The number of dispensations and the mean
daily DDD of OAT opioids did not affect the number of
dispensations of benzodiazepines and z-hypnotics, or
gabapentinoids. Being dispensed a benzodiazepine or
z-hypnotic was associated with aging 46–55 years or
being above 56 years of age rather than aging below
25 years, gender women, using methadone rather than
buprenorphine as OAT opioid or being dispensed at
least once a non-OAT opioid, or a gabapentinoid in
2017. Similar results were substantially found in the
period from 2013 to 2016. Oxazepam and zopiclone
were the most frequently dispensed benzodiazepine
and z-hypnotic, respectively, and pregabalin was pre-
scribed twice as often per patient per year as gaba-
pentin throughout the study period. Discontinuation
of OAT was not associated with changes in the dis-
pensation rates or the mean daily doses of benzodiaz-
epines or z-hypnotics, or gabapentinoids.
Our findings were in line with dispensation rates of ben-
zodiazepines, z-hypnotics, and gabapentinoids in the OAT
population in the United Kingdom in the period from
Table 3 The proportion of patients who were dispensed benzodiazepines, z-hypnotics, and gabapentinoids, respectively
Year 2013 2014 2015 2016 2017
Benzodiazepines or z-hypnotics No. %a No. %a No. %a No. %a No. %a
Oxazepam 2094 28 2091 27 2124 27 2183 28 2229 29
Diazepam 1216 16 1251 16 1222 16 1272 17 1289 17
Zopiclone 1026 14 964 12 932 12 936 12 863 11
Nitrazepam 757 10 759 10 747 10 737 10 701 9
Clonazepam 479 6 432 6 362 5 331 4 268 4
Zolpidem 351 5 359 5 333 4 315 4 327 4
Alprazolam 305 4 304 4 237 3 206 3 196 3
Flunitrazepam 41 1 38 0 37 0 32 0 36 0
Gabapentinoids No. %a No. %a No. %a No. %a No. %a
Pregabalin 487 6 449 6 491 6 523 7 591 8
Gabapentin 260 3 240 3 277 4 291 4 310 4
No. Number of patients, OAT Opioid agonist therapy
aPercent of all patients who were dispensed an OAT opioid
The table displays the proportion of all OAT patients who were dispensed different benzodiazepines, z-hypnotics, and gabapentinoids
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1998 to 2014 [9]. Further, the dispensation rates were
higher for being dispensed a benzodiazepine or a gabapen-
tinoid and lower for being dispensed a z-hypnotic com-
pared with the OAT population in Sweden in the period
2005 to 2013 [1]. In Norway, the proportion of OAT pa-
tients who were dispensed benzodiazepines or z-hypnotics
was at least as high as comparable descriptive analyses of
benzodiazepine dispensations in 2005 [23]. Moreover, the
proportion of the general Norwegian population was dis-
pensed a benzodiazepine or z-hypnotic decreased rela-
tively on 1.2% per year from 10.8% in 2015 to 10.4% in
2017, whereas pregabalin increased by 3.5% per year, and
gabapentin increased by 5.8% per year in the same period
[24]. The dispensation rates of all these potentially addict-
ive drugs were substantially higher in the OAT popula-
tion. For gabapentinoids, the dispensation rates were
increasing in both the OAT population and the general
Norwegian population in the study period.
The reasons for the increasing use of gabapentinoids
in the OAT population are lacking. In the past decade,
gabapentinoids, particularly pregabalin, were placed
under scrutiny due to the risk of addiction [16], and pre-
scribers have become aware of the risk of prescribing
these drugs to patients with a history of drug addiction
[1]. Although, it is remarkable that the dispensation rate
of gabapentinoids was increasing, and pregabalin was
dispensed twice as frequently as gabapentin. The reason
may be a high prevalence of psychiatric comorbidities
like anxiety in the OAT population [25–27]. Further
Table 4 Logistic regression analyses of variables associated with







cOR p-value aOR (95% CI) p-value
Age
- ≤ 25 1.0 (ref.) 1.0 (ref.)
- 26-35 1.0 .80 0.9 (0.6–1.4) .76
- 36-45 1.0 .85 1.0 (0.7–1.5) .94
- 46-55 1.6 .02 1.7 (1.1–2.5) .05
- ≥ 56 1.9 < .01 1.2 (1.1–1.3) .01
Gender
- Men 1.0 (ref.) 1.0 (ref.)
- Women 1.2 < .01 1.2 (1.1–1.3) < .01
The number of dispensations of OAT opioids
- ≥ 52 1.0 (ref.) 1.0 (ref.)
- 13-51 1.3 < .01 1.2 (1.1–1.5) .01
- 7-12 1.1 .27 1.0 (0.9–1.3) .73




1.0 (ref.) 1.0 (ref.)
- Methadone (incl.
Levomethadone)
1.4 < .01 1.3 (1.2–1.4) < .01
Dispensed a non-
OAT opioid
3.5 < .01 3.0 (2.6–3.5) < .01
Dispensed a gabapentinoid 3.0 < .01 2.5 (2.1–3.0) < .01
b)
2017 Dispensed a gabapentinoid
N = 845
cOR p-value aOR (95% CI) p-value
Age
- ≤ 25 1.0 (ref.) 1.0 (ref.)
- 26-35 1.1 .71 1.2 (0.6–2.2) .60
- 36-45 1.0 .90 1.1 (0.6–2.0) .79
- 46-55 1.0 .99 0.9 (0.5–1.7) .75
- ≥ 56 1.0 .95 0.8 (0.4–1.5) .45
Gender
- Men 1.0 (ref.) 1.0 (ref.)
- Women 1.3 < .01 1.1 (1.0–1.3) .16
The number of dispensations of OAT opioids
- ≥ 52 1.0 (ref.) 1.0 (ref.)
- 13-51 0.9 .62 0.9 (0.7–1.1) .31
- 7-12 1.0 .95 0.9 (0.7–1.3) .72
Table 4 Logistic regression analyses of variables associated with
being dispensed a benzodiazepine or z-hypnotic, and a
gabapentinoid (Continued)




1.0 (ref.) 1.0 (ref.)
- Methadone (incl.
Levomethadone)
1.1 .46 1.1 (0.9–1.3) .41
Dispensed a non-
OAT opioid




3.0 < .01 2.5 (2.1–3.0) <.01
cOR crude odds ratio, aOR adjusted odds ratio, CI Confidence interval, and OAT
Opioid agonist therapy
aThe last type of dispensed OAT opioid
Table a) and b) display unadjusted (crude) and adjusted odds ratio for all
independent variables of patients who were dispensed at least a
benzodiazepine or z-hypnotic, and a gabapentinoid, respectively, in 2017 in
Norway. a) Being dispensed at least a benzodiazepine or z-hypnotic was
defined as a dependent variable, and age, gender, ‘the number of
dispensations of OAT opioids,’ ‘OAT opioids,’ ‘dispensed a non-OAT opioid,’
and ‘dispensed a gabapentinoid’ were defined as categorical and independent
variables. b) Being dispensed a gabapentinoid was defined as a dependent
variable, and age, gender, ‘the number of dispensations of OAT opioids,’ ‘OAT
opioids,’ ‘dispensed a non-OAT opioid,’ and ‘dispensed a benzodiazepine or z-
hypnotic’ were defined as categorical and independent variables
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studies evaluating reasons for the increasing gabapenti-
noid use among patients on OAT is required.
Being dispensed a benzodiazepine or z-hypnotic was par-
ticularly associated with being dispensed non-OAT opioids,
and gabapentinoids, as well as methadone rather than
buprenorphine as the type of OAT opioid. Chronic non-
malignant pain like pain in muscles and skeleton is highly
prevalent in the OAT population using methadone as an
OAT opioid and affects up to 68% in some studies [28–31].
Having chronic non-malignant pain on OAT is strongly as-
sociated with using benzodiazepines [26, 27], and the pres-
ence of psychiatric comorbidities such as anxiety and
depression [31]. Even though the prevalence of chronic
non-malignant pain in the Norwegian OAT population is
uncertain, one can assume that chronic non-malignant pain
was an essential explanation for the association between
the dispensation of benzodiazepines and gabapentinoids
and using methadone on OAT in this study.
Overall, there is substantial evidence that OAT pro-
tects against overdose-related deaths and injecting
opioid use [32, 33]. Nevertheless, the mortality increases
significantly among patients on OAT if dispensed
benzodiazepines, z-hypnotics, or gabapentinoids [1, 2].
Therefore, the guidelines in several European countries
recommend careful dispensation of potentially addictive
drugs to these patients on OAT [34, 35]. However,
being dispensed of a potentially addictive drug is
not necessarily wrong, and the reasons for these
dispensations may be multifactorial. Physical and
mental comorbidities are highly prevalent among
patients on OAT, which predict and defend the
dispensations of potentially addictive drugs [25–27].
In a few marginalized cases with several addictions,
it is argued that dispensations of benzodiazepines
decrease mortality if low dosed benzodiazepines re-
place illegal drug consumption [2]. Nevertheless, it
should be a better awareness of whether such dis-
pensations are medically indicated on patients on
OAT taken our findings into consideration. Improv-
ing prescription routines among general physicians,
application of strict monitoring systems, and a close
co-operation with specialized addiction health care
center may be considered as some of the essential
approaches to strive for optimal conditions in cases
Fig. 2 Daily doses of benzodiazepines and z-hypnotics among patients who discontinued OAT. Legends: CI = Confidence interval, df = degrees of
freedom, lowest = lowest equipotency dose, highest = highest equipotency dose, and OAT = opioid agonist therapy. 1) Paired t-test, df = 155,
comparing mean daily dose ≥0 - ≤90 days to baseline related to discontinuation. 2) Paired t-test, df = 24, comparing mean daily dose ≥0 - ≤90
days to baseline related to discontinuation. 3) Paired t-test, df = 32, comparing mean daily dose ≥0 - ≤90 days to ≥90 - < 0 days related to
discontinuation. Displays the daily doses of dispensed benzodiazepines and z-hypnotics, in the following period related to the date of the last
dispensation of an OAT opioids: 1) 180–90 days before discontinuation (baseline), 2) 90–0 days before discontinuation, and 3) 0–90 days after
discontinuation. Discontinuation was defined as all patients on OAT who had the last dispensation of an OAT opioid in the period January 1,
2017, to September 30, 2017, and no dispensation until the end of March 31, 2018. The daily doses were stated in mean, median, 25 percentile,
and 75 percentile. An equipotency table for benzodiazepines and z-hypnotics were used to make sensitivity analyses, displaying the lowest
equipotency dose and the highest equipotency dose of the included benzodiazepines and z-hypnotics. The results were presented in
parentheses. All dispensed benzodiazepines and z-hypnotics were summarized per year
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on OAT where several potentially addictive drugs
are medically indicated.
Strengths and limitations
Using Norwegian registry data had some strengths.
Pharmacy records are viewed to be more valid than both
medical records and data collected from questionnaires
and interviews. Because practically all dispensed drugs
are registered in the database, completeness, and preci-
sion of all received information is high, and the potential
for information biases is low.
This study also had some limitations. The NorPD only
receives information about dispensed drugs, and we
cannot know whether the drugs have been consumed.
Second, due to that a minor part of reimbursed prescrip-
tions being received through the Norwegian Health
Economics Administration (HELFO), the medical indica-
tions for these dispensations are not available for the re-
searchers through NorPD. For example, clonazepam,
pregabalin, and gabapentin may be dispensed on the
medical indication of epilepsy, while oxazepam or diaze-
pam may be used preferably for detoxifications, or treat-
ment of short-term anxiety or sleeping disorder. Third,
the number of dispensations may be incomplete regis-
tered by the pharmacies. For OAT opioids, the self-
reporting survey of OAT showed that the mean number
of dispensation per patient was four times a week [15].
This finding may indicate that the number of dispensa-
tions is underestimated in our study. In order to adjust
for this uncertainty to some extent, the mean daily dose
calculated by summing the dispensed DDD, divided by
the number of days between the first and the last dis-
pensation were used. Fourth, slightly less than 10% of
OAT opioids are dispensed in addiction specialist out-
patient clinics, and those are not necessarily registered
in NorPD. Some of these outpatient clinics ordered
OAT opioids directly from pharmacies without linking
to a personal identification number. These patients were
lost in this study [15].
Conclusion
The dispensation rates of benzodiazepines, z-hypnotics,
and gabapentinoids to patients receiving OAT in
Norway are high. A high burden of disease among
patients on OAT may be an essential explanation.
Future policies need to debate the indications for
dispensations of benzodiazepines, z-hypnotics, and
gabapentinoids explicitly in guidelines on OAT as
well as make requirements for dispensation authority.
More randomized controlled trials evaluating the ben-
efits and risks of such co-dispensation with sufficient
power are required.
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